CMEOF (Creo Medical Group) Growth Rank: 7 (As of Aug. 13, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CMEOF Creo Medical Group PLC CMEOF
29 GF Score
Price $0.23
GF Value $0.39
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Creo Medical Group Growth Rank?

Creo Medical Group CMEOF 29 Growth Rank is 7 as of Aug. 13, 2026, which is at its 10-year median of 7.00. GuruFocus rates CMEOF with a GF Score™ of 29/100 and a GF Value™ of $0.39 (Possible Value Trap). The stock has 6 warning signs investors should review.

Creo Medical Group has the Growth Rank of 7.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Creo Medical Group Growth Rank Related Terms

CMEOF vs ABT, SYK, MDT: Growth Rank Comparison

For the Medical Devices subindustry, Creo Medical Group's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Creo Medical Group Growth Rank vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Creo Medical Group's Growth Rank distribution charts can be found below:

* The bar in red indicates where Creo Medical Group's Growth Rank falls into.


CMEOF
29GF Score
Creo Medical Group PLC CMEOF
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 7 mean?
Creo Medical Group (CMEOF) has a Growth Rank of 7 as of Aug. 13, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Creo Medical Group and its competitors. This is near median its historical median of 7.00. Over the past decade, Creo Medical Group's Growth Rank has ranged from 7.00 to 7.00.
Is Creo Medical Group's Growth Rank too high?
Creo Medical Group's current Growth Rank of 7 is near median its 10-year median of 7.00. Over the past 10 years, this metric has ranged from a low of 7.00 to a high of 7.00. Overall, Creo Medical Group has a GF Score™ of 29/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Creo Medical Group's Growth Rank compare to ABT and SYK?
Creo Medical Group's Growth Rank of 7 can be compared against companies in the Medical Devices & Instruments industry. Historically, Creo Medical Group's own Growth Rank has ranged from 7.00 to 7.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Medical Devices & Instruments company?
A good Growth Rank depends on the Medical Devices & Instruments industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Creo Medical Group and its competitors. Creo Medical Group's current Growth Rank is 7, which is near median its own 10-year median of 7.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Creo Medical Group stock overvalued right now?
Based on GuruFocus' analysis, Creo Medical Group (CMEOF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.39, compared to a current price of $0.23 — trading 42.2% below its estimated fair value. The current Growth Rank is 7, which is near median its 10-year median of 7.00. Creo Medical Group's overall GF Score™ is 29/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Creo Medical Group (CMEOF), the current Growth Rank is 7 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Creo Medical Group (CMEOF) Overvalued in 2026?

Based on GuruFocus' analysis, Creo Medical Group stock appears to be undervalued. The current stock price of $0.23 is trading 42.2% below its estimated GF Value™ of $0.39. GuruFocus considers Creo Medical Group to be Possible Value Trap.

Key valuation signals for CMEOF:

  • Growth Rank: 7 (near median its 10-year median of 7.00)
  • GF Value™: $0.39 vs. price of $0.23 (42.2% below fair value)
  • GF Score™: 29/100 with 6 warning signs

No single metric tells the full story. See the CMEOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Creo Medical Group Business Description

Other Exchanges CREO:UK
Address Beaufort Park Way, Unit 2, Creo House, Beaufort Park, Chepstow, GBR, NP16 5UH
Creo Medical Group PLC is a medical device company engaged in providing services in the field of surgical endoscopy. The company has developed a platform called Croma which is an electrosurgical platform to deliver microwave and bipolar radiofrequency through a single accessory port. The reportable segment of the company is the research and development of electrosurgical medical devices relating to the field of surgical endoscopy. Geographically, the company generates a majority of its revenue from United Kingdom and the rest from Europe and the rest of the world.
29GF Score

Get the complete analysis for CMEOF

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.23
Price
$0.39
GF Value